Virginia Retirement Systems ET AL Sells 21,300 Shares of United Therapeutics Co. (UTHR)

Virginia Retirement Systems ET AL lowered its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 28.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,000 shares of the biotechnology company’s stock after selling 21,300 shares during the period. Virginia Retirement Systems ET AL owned 0.12% of United Therapeutics worth $6,778,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fox Run Management L.L.C. increased its stake in shares of United Therapeutics by 85.2% during the third quarter. Fox Run Management L.L.C. now owns 4,406 shares of the biotechnology company’s stock worth $563,000 after purchasing an additional 2,027 shares during the period. Thompson Siegel & Walmsley LLC increased its stake in United Therapeutics by 3.1% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 559,107 shares of the biotechnology company’s stock worth $63,263,000 after acquiring an additional 16,638 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its stake in United Therapeutics by 18.9% during the 2nd quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 33,400 shares of the biotechnology company’s stock worth $3,779,000 after acquiring an additional 5,300 shares during the period. Glen Harbor Capital Management LLC increased its stake in United Therapeutics by 26.0% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 22,976 shares of the biotechnology company’s stock worth $2,600,000 after acquiring an additional 4,736 shares during the period. Finally, Neuburgh Advisers LLC increased its stake in United Therapeutics by 26.0% during the 2nd quarter. Neuburgh Advisers LLC now owns 48,824 shares of the biotechnology company’s stock worth $5,525,000 after acquiring an additional 10,064 shares during the period. Institutional investors own 95.71% of the company’s stock.

A number of equities analysts have commented on UTHR shares. Wedbush raised their price objective on United Therapeutics from $234.00 to $253.00 and gave the stock an “outperform” rating in a research note on Thursday, August 2nd. Zacks Investment Research lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Sunday, July 15th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $118.00 to $126.00 and gave the stock a “neutral” rating in a research note on Friday, November 2nd. Standpoint Research upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 12th. Finally, BidaskClub upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $136.25.

In other United Therapeutics news, Director Richard Giltner sold 3,240 shares of the firm’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total value of $419,191.20. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Christopher Causey sold 810 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $119.00, for a total value of $96,390.00. Following the completion of the sale, the director now directly owns 1,555 shares in the company, valued at approximately $185,045. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,860 shares of company stock worth $611,161. Company insiders own 8.20% of the company’s stock.

Shares of UTHR stock opened at $114.39 on Friday. The firm has a market capitalization of $5.08 billion, a price-to-earnings ratio of 8.31, a price-to-earnings-growth ratio of 26.99 and a beta of 1.23. United Therapeutics Co. has a fifty-two week low of $100.57 and a fifty-two week high of $152.55. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.05 and a current ratio of 4.32.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.23 by ($0.81). The business had revenue of $412.70 million during the quarter, compared to analyst estimates of $378.22 million. United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The company’s revenue for the quarter was down 7.4% compared to the same quarter last year. During the same period in the prior year, the business posted $4.69 EPS. On average, analysts forecast that United Therapeutics Co. will post 14.39 earnings per share for the current year.

WARNING: “Virginia Retirement Systems ET AL Sells 21,300 Shares of United Therapeutics Co. (UTHR)” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/11/10/virginia-retirement-systems-et-al-sells-21300-shares-of-united-therapeutics-co-uthr.html.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Story: NASDAQ Stock Market Explained

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply